Battling malaria: Strengthening the U.S. Military Malaria Vaccine Program

Battling Malaria: Strengthening the U.S. Military Malaria Vaccine Program

Volumn , Issue , 2006, Pages 1-121

  Graves, Patricia M ^a   Levine, Myron M ^b,c,d,e  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

^e UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988258941     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.17226/11656     Document Type: Book

References (128)

1. Aggarwal A, Kumar S, Jaffe R, Hone D, Gross M, Sadoff J. 1990. Oral Salmonella: Malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. Journal of Experimental Medicine 172:1083-1090.
2. Alloueche A, Milligan P, Conway DJ, Pinder M, Bojang K, Doherty T, Tornieporth N, Cohen J, Greenwood BM. 2003. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. American Journal of Tropical Medicine and Hygiene 68(1):97-101.
3. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. 2004. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 364(9443):1411-1420.
4. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR. 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502):2012-2018.
5. Amador R, Moreno A, Valero V, Murillo L, Mora AL, Rojas M, Rocha C, Salcedo M, Guzman F, Espejo F, Nuñez F, Patarroyo M. 1992. The first field trials of the chemically synthesized malaria vaccine SPf66: Safety, immunogenicity and protectivity. Vaccine 10(3):179-184.
6. Anderson RJ, Hannan CM, Gilbert SC, Laidlaw SM, Sheu EG, Korten S, Sinden R, Butcher GA, Skinner MA, Hill AV. 2004. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. Journal of Immunology 172(5):3094-3100.
7. Ballou WR. 2005. Malaria vaccines in development. Expert Opinion in Emerging Drugs 10(3):489-503.
8. Ballou WR, Sherwood JA, Neva FA, Gordon DM, Wirtz RA, Wassermann GF, Diggs CL, Hoffman SL, Hollingdale MR, Schneider I, Young JF, Reeve P, Chulay JD. 1987. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1(8545):1277-1281.
9. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, Kester KE, Lanar DE, Lyon J, Hill AV, Pan W, Cohen JD. 2004. Update on the clinical development of candidate malaria vaccines. American Journal of Tropical Medicine and Hygiene 71(suppl 2):239-247.
10. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial. Lancet 358(9297):1927-1934.
11. Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ. 2005. Safety and immunogenicty of RTS,S/ AS02A candidate malaria vaccine in Gambian children. Vaccine 23(32):4148-4157.
12. Breman JG, Alilio MS, Mills A. 2004. Conquering the intolerable burden of malaria: What's new, what's needed: A summary. American Journal of Tropical Medicine and Hygiene 71(suppl 2):1-15.
13. Brown AE, Singharaj P, Webster HK, Pipithkul J, Gordon DM, Boslego JW, Krinchai K, Suarchawaratana P, Wongsrichanalai C, Ballou WR, Permpanich B, Kain KC, Hollingdale MR, Wittes J, Que JU, Gross M, Cryz SJ, Sadoff JC. 1994. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 12(2):102-108.
14. Carlton JM, Angiuoli SV, Suh BB, Kooij TW, Pertea M, Silva JC, Ermolaeva MD, Allen JE, Selengut JD, Koo HL, Peterson JD, Pop M, Kosack DS, Shumway MF, Bidwell SL, Shallom SJ, van Aken SE, Riedmuller SB, Feldblyum TV, Cho JK, Quackenbush J, Sedegah M, Shoaibi A, Cummings LM, Florens L, Yates JR, Raine JD, Sinden RE, Harris MA, Cunningham DA, Preiser PR, Bergman LW, Vaidya AB, van Lin LH, Janse CJ, Waters AP, Smith HO, White OR, Salzberg SL, Venter JC, Fraser CM, Hoffman SL, Gardner MJ, Carucci DJ. 2002. Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 419(6906):512-519.
15. CDC (Centers for Disease Control and Prevention). 1993. Malaria among U.S. military personnel returning from Somalia, 1993. Morbidity and Mortality Weekly Report. 42(27):523-526.
16. CDC. 2002. Centers for Disease Control and Prevention Public Health Image Library. [Online]. Image number 3405. Alexander J da Silva, Melanie Moser. Available: http:// phil.cdc.gov/phil/ [accessed May 3, 2006].
17. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, Quakyi IA, Carter R, Trosper JH, Hockmeyer WT. 1986. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 35(1):66-68.
18. Clyde DF. 1975. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. American Journal of Tropical Medicine and Hygiene 24(3):397-401.
19. Clyde DF. 1990. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: A review of the University of Maryland studies, 1971-75. Bulletin of the World Health Organization 68(suppl):9-12.
20. Cohen S, McGregor IA, Carrington S. 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192:733-737.
21. Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, Maloy WL, Haynes JD, Schneider I, Roberts D, Sander GS, Reddy EP, Diggs CL, Miller LH. 1984. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225(4662):593-599.
22. Davis JR. 1994. Laboratory methods for the conduct of experimental malaria challenge of volunteers. Vaccine 12(4):321-327.
23. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrobial Agents and Chemotherapy 16(6):710-718.
24. Doolan DL, Hoffman SL. 2000. The complexity of protective immunity against liver-stage malaria. Journal of Immunology 165(3):1453-1462.
25. Downs WG, Harper PA, Lisamsky ET. 1947. Malaria and other insect-borne diseases in the South Pacific Campaign, 1942-1945. II Epidemiology of insect-borne diseases in Army troops. American Journal of Tropical Medicine 27:69-89.
26. Dunachie SJ, Hill AV. 2003. Prime-boost strategies for malaria vaccine development. Journal of Experimental Biology 206(Pt 21):3771-3779.
27. Edozien JC. 1961. The effect of malaria on the serum gamma globulin concentration in Africans. West African Medical Journal 10:304-310.
28. Ellis J, Ozaki LS, Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS, Godson GN. 1983. Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 302(5908):536-538.
29. Enea V, Ellis J, Zavala F, Arnot DE, Asavanich A, Masuda A, Quakyi I, Nussenzweig RS. 1984. DNA cloning of Plasmodium falciparum circumsporozoite gene: Amino acid sequence of repetitive epitope. Science 225(4662):628-630.
30. Epstein JE, Charoenvit Y, Kester KE, Wang R, Newcomer R, Fitzpatrick S, Richie TL, Tornieporth N, Heppner DG, Ockenhouse C, Majam V, Holland C, Abot E, Ganeshan H, Berzins M, Jones T, Freydberg CN, Ng J, Norman J, Carucci DJ, Cohen J, Hoffman SL. 2004. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 22(13-14):1592-1603.
31. Ferreira A, Schofield L, Enea V, Schellekens H, van der Meide P, Collins WE, Nussenzweig RS, Nussenzweig V. 1986. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 232(4752):881-884.
32. Fries LF, Gordon DM, Schneider I, Beier JC, Long GW, Gross M, Que JU, Cryz SJ, Sadoff JC. 1992. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infection and Immunity 60(5):1834-1839.
33. Garcon N, Heppner DG, Cohen J. 2003. Development of RTS,S/AS02: A purified subunitbased malaria vaccine candidate formulated with a novel adjuvant. Expert Reviews of Vaccines 2(2):231-238.
34. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. 2002a. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419(6906):498-511.
35. Gardner MJ, Shallom SJ, Carlton JM, Salzberg SL, Nene V, Shoaibi A, Ciecko A, Lynn J, Rizzo M, Weaver B, Jarrahi B, Brenner M, Parvizi B, Tallon L, Moazzez A, Granger D, Fujii C, Hansen C, Pederson J, Feldblyum T, Peterson J, Suh B, Angiuoli S, Pertea M, Allen J, Selengut J, White O, Cummings LM, Smith HO, Adams MD, Venter JC, Carucci DJ, Hoffman SL, Fraser CM. 2002b. Sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14. Nature 419(6906):531-534.
36. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP. 2002. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. Journal of Infectious Diseases 185(6):820-827.
37. Genton B, D'Acremont V, Lurati F, Verhage D, Hermsen R, Audran R, Reymond C, Spertini F, Sauerwein R. 2005. Randomized, double-blind placebo-controlled Phase IIa trial to test efficacy of the malaria vaccine PfCS102 to protect non-immune volunteers against falciparum challenge. Proceedings of the Multilateral Initiative on Malaria meeting, Yaounde, Cameroon, Nov 14 to 17, 2005.
38. Good MF. 2001. Towards a blood-stage vaccine for malaria: Are we following all the leads? Nature Reviews Immunology 1(2):117-125.
39. Good MF, Kumar S, Weiss WR, Miller LH. 1989. T-cell antigenic sites of the malaria circumsporozoite protein. Blood 74(3):895-900.
40. Graves P, Gelband H. 2003. Vaccines for preventing malaria. Cochrane Database of Systematic Reviews (1):CD000129.
41. Greco M. 2004. Development and supply of vaccines: An industry perspective. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, eds. New Generation Vaccines. 3rd ed. New York: Marcel Dekker Inc. Pp. 75-87.
42. Harper PA, Lisansky ET, Sasse BE. 1947. Malaria and other insect-borne diseases in the South Pacific campaign, 1942-1945: I General aspects and control measures. American Journal of Tropical Medicine 27:1-67.
43. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. 2004. The global distribution and population at risk of malaria: Past, present, and future. Lancet Infectious Dieasess 4(6):327-336.
44. Haynes JD, Diggs CL, Hines FA, Desjardins RE. 1976. Culture of human malaria parasites Plasmodium falciparum. Nature 263(5580):767-769.
45. Haynes JD, Moch JK, Smoot DS. 2002. Erythrocytic malaria growth or invasion inhibition assays with emphasis on suspension culture GIA. Methods in Molecular Medicine 72:535-554.
46. Heppner, DG. 2006 (January 23). U.S. military malaria research and vaccine program. Protein-based strategy. Paper presented at the Institute of Medicine Workshop on Military Malaria Vaccine Development, Silver Spring, Maryland. Institute of Medicine Committee on DoD Malaria Vaccine Research-A Program Review.
47. Heppner DG, Gordon DM, Gross M, Wellde B, Leitner W, Krzych U, Schneider I, Wirtz RA, Richards RL, Trofa A, Hall T, Sadoff JC, Boerger P, Alving CR, Sylvester DR, Porter TG, Ballou WR. 1996. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. Journal of Infectious Diseases 174(2):361-366.
48. Heppner DG, Cummings JF, Ockenhouse C, Kester KE, Lyon JA, Gordon DM. 2001. New World monkey efficacy trials for malaria vaccine development: Critical path or detour? Trends in Parasitology 17(9):419-425.
49. Heppner DG, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. 2005. Towards an RTS,S-based, multistage, multi-antigen vaccine against falciparum malaria: Progress at the Walter Reed Army Institute of Research. Vaccine 23(17-18):2243-2250.
50. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillessen D, Nardin E, Nussenzweig RS, Nussenzweig V, Hollingdale MR, Levine MM. 1987. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328(6127):257-259.
51. Herrington DA, Clyde DF, Murphy JR, Baqar S, Levine MM, do Rosario V, Hollingdale MR. 1988. A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines. Tropical and Geographical Medicine 40(2):124-127.
52. Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, Nussenzweig RS, Clyde D, Edelman R. 1991. Successful immunization of humans with irradiated malaria sporozoites: Humoral and cellular responses of the protected individuals. American Journal of Tropical Medicine and Hygiene 45(5):539-547.
53. Herrington DA, Losonsky GA, Smith G, Volvovitz F, Cochran M, Jackson K, Hoffman SL, Gordon DM, Levine MM, Edelman R. 1992. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. Vaccine 10(12):841-846.
54. Hoffman SL, Edelman R, Bryan JP, Schneider I, Davis J, Sedegah M, Gordon D, Church P, Gross M, Silverman C, Hollingdale M, Clyde D, Sztein M, Losonsky G, Paparello S, Jone TR. 1994. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. American Journal of Tropical Medicine and Hygiene 51(5):603-612.
55. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL. 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. Journal of Infectious Diseases 185(8):1155-1164.
56. Hollingdale MR, McCormick CJ, Heal KG, Taylor-Robinson AW, Reeve P, Boykins R, Kazura JW. 1998. Biology of malarial liver stages: Implications for vaccine design. Annals of Tropical Medicine and Parasitology 92(4):411-417.
57. IOM (Institute of Medicine). 1996. Vaccines Against Malaria: Hope in a Gathering Storm. Washington, D.C.: National Academy Press. P. 30.
58. IOM. 2002. Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military. Washington, D.C.: The National Academies Press. P. 133.
59. IOM. 2004. Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents. Washington, D.C.: The National Academies Press. P. 160.
60. Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, Krzych U, Palmer DR, Egan A, Diggs C, Ballou WR, Hall BF, Kaslow D. 1999. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18(5-6):531-539.
61. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR. 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. Journal of Infectious Diseases 183(4):640-647.
62. Kotwal RS, Wenzel RB, Sterling RA, Porter WD, Jordan NN, Petrucelli BP. 2005. An outbreak of malaria in U.S. Army rangers returning from Afghanistan. Journal of the American Medical Association 293(2):212-215.
63. Krzych U, Lyon JA, Jareed T, Schneider I, Hollingdale MR, Gordon DM, Ballou WR. 1995. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. Journal of Immunology 155(8):4072-4077.
64. Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J. 1999. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. Journal of Infectious Diseases 180(5):1656-1664.
65. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL. 2000. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18(18):1893-1901.
66. Levine MM, Campbell JD, Kotloff KL. 2002. Overview of vaccines and immunisation. British Medical Bulletin 62:1-13.
67. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F. 1993. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proceedings of the National Academy of Sciences USA 90(11):5214-5218.
68. Lyon JA, Geller RH, Haynes JD, Chulay JD, Weber JL. 1986. Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene. Proceedings of the National Academy of Sciences USA 83(9):2989-2993.
69. Lyon JA, Carter JM, Thomas AW, Chulay JD. 1997. Merozoite surface protein-1 epitopes recognized by antibodies that inhibit Plasmodium falciparum merozoite dispersal. Molecular and Biochemical Parasitology 90(1):223-234.
70. Malaria R&D Alliance. 2005. Malaria Research and Development: An Assessment of Global Investment. Seattle, WA: Program for Appropriate Technology in Health.
71. Malik A, Egan JE, Houghten RA, Sadoff JC, Hoffman SL. 1991. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proceedings of the National Academy of Sciences USA 88(8):3300-3304.
72. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP. 2005. Phase 1 clinical trial of apical membrane antigen 1: An asexual blood-stage vaccine for Plasmodium falciparum malaria. Infection and Immunity 73(6):3677-3685.
73. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine 9(6):729-735.
74. Mellouk S, Green SJ, Nacy CA, Hoffman SL. 1991. IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. Journal of Immunology 146(11):3971-3976.
75. Moorthy VS, Good MF, Hill AV. 2004a. Malaria vaccine developments. Lancet 363(9403):150-156.
76. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, Hill AS. 2004b. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. Public Library of Science Medicine 1(2):e33.
77. Mueller AK, Labaied M, Kappe SH, Matuschewski K. 2005. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433(7022):164-167.
78. Nardin EH, Nussenzweig RS. 1993. T cell responses to pre-erythrocytic stages of malaria: Role in protection and vaccine development against pre-erythrocytic stages. Annual Review of Immunology 11:687-727.
79. Nussenzweig V, Nussenzweig RS. 1989. Rationale for the development of an engineered sporozoite malaria vaccine. Advances in Immunology 45:283-334.
80. Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, Holder AA, Nwagwu M. 2002. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infection and Immunity 70(9):5328-5331.
81. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Horii T, Paoletti E, Ballou WR. 1998. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Journal of Infectious Diseases 177(6):1664-1673.
82. Ockenhouse CF, Magill A, Smith D, Milhous W. 2005. History of U.S. military contributions to the study of malaria. Military Medicine 170(4):12-16.
83. Ophorst OJ, Radosevic K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M. 2006. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infection and Immunity 74(1):313-320.
84. Patarroyo ME, Romero P, Torres ML, Clavijo P, Moreno A, Martinez A, Rodriguez R, Guzman F, Cabezas E. 1987. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328(6131):629-632.
85. Richie T. 2006 (January 23). Development of a multivalent, multistage vaccine against P.falciparum malaria using molecular approaches. Paper presented at the Institute of Medicine Workshop on Military Malaria Vaccine Development, Silver Spring, Maryland. Institute of Medicine Committee on DoD Malaria Vaccine Research-A Program Review.
86. Richie TL, Saul A. 2002. Progress and challenges for malaria vaccines. Nature 415(6872):694-701.
87. Rieckmann KH. 1990. Human immunization with attenuated sporozoites. Bulletin of the World Health Organization 68(suppl):13-16.
88. Rieckmann KH, Beaudoin RL, Cassells JS, Sell KW. 1979. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bulletin of the World Health Organization 57(suppl 1):261-265.
89. Roadmap. 2006. Malaria Vaccine Technology Roadmap Working Group Report. [Online]. Available: http://www.malariavaccineroadmap.net/pdfs/report2005.pdf [accessed January 23, 2006].
90. Robson KJ, Hall JR, Jennings MW, Harris TJ, Marsh K, Newbold CI, Tate VE, Weatherall DJ. 1988. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 335(6185):79-82.
91. Rodrigues M, Nussenzweig RS, Zavala F. 1993. The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology 80(1):1-5.
92. Rodrigues M, Li S, Murata K, Rodriguez D, Rodriguez JR, Bacik I, Bennink JR, Yewdell JW, Garcia-Sastre A, Nussenzweig RS, Esteban M, Palese P, Zavala F. 1994. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. Journal of Immunology 153(10):4636-4648.
93. Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. Journal of Immunology 158(3):1268-1274.
94. Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M. 1998. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16(19):1812-1817.
95. Rogers WO, Malik A, Mellouk S, Nakamura K, Rogers MD, Szarfman A, Gordon DM, Nussler AK, Aikawa M, Hoffman SL. 1992. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proceedings of the National Academy of Sciences USA 89(19):9176-9180.
96. Rogers WO, Baird JK, Kumar A, Tine JA, Weiss W, Aguiar JC, Gowda K, Gwadz R, Kumar S, Gold M, Hoffman SL. 2001. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infection and Immunity 69(9):5565-5572.
97. Rogers WO, Weiss WR, Kumar A, Aguiar JC, Tine JA, Gwadz R, Harre JG, Gowda K, Rathore D, Kumar S, Hoffman SL. 2002. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infection and Immunity 70(8):4329-4335.
98. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. 1989. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341(6240):323-326.
99. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P. 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. American Journal of Tropical Medicine and Hygiene 45(3):297-308.
100. Sadoff JC, Ballou WR, Baron LS, Majaran WR, Brey RN, Hockmeyer WT, Young JF, Cryz SJ, Ou J, Lowell GH, Chulay JD.1988. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240(4850):336-338.
101. Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS. 1987a. Interferongamma inhibits the intrahepatocytic development of malaria parasites in vitro. Journal of Immunology 139(6):2020-2025.
102. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V. 1987b. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330(6149):664-666.
103. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. 1994. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proceedings of the National Academy of Science USA 91(21):9866-9870.
104. Sedegah M, Jones TR, Kaur M, Hedstrom R, Hobart P, Tine JA, Hoffman SL. 1998. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proceedings of the National Academy of Sciences USA 95(13):7648-7653.
105. Sedegah M, Charoenvit Y, Minh L, Belmonte M, Majam VF, Abot S, Ganeshan H, Kumar S, Bacon DJ, Stowers A, Narum DL, Carucci DJ, Rogers WO. 2004. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Therapy 11(5):448-456.
106. Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, Raney JJ, Aniagolu JU, Green SJ. 1994. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: Involvement of interferon gamma and CD8+ T cells. Journal of Experimental Medicine 180(1):353-358.
107. Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB, Strickland GT, Gordon DM, Ballou WR, Bales JD Jr, Wirtz RA, Wittes J, Gross M, Que JU, Cryz SJ, Oster CN, Roberts CR, Sadoff JC. 1996. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine 14(8):817-827.
108. Snow RW, Korenromp EL, Gouws E. 2004. Pediatric mortality in Africa: Plasmodium falciparum malaria as a cause or risk? American Journal of Tropical Medicine and Hygiene 71(suppl 2):16-24.
109. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434(7030):214-217.
110. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. New England Journal of Medicine 336(2):86-91.
111. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CE, Garcon N, Schwenk R, Lanar DE, Sun P, Momin P, Wirtz RA, Golenda C, Slaoui M, Wortmann G, Holland C, Dowler M, Cohen J, Ballou WR. 1998. Long-term efficacy and immune response following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases 178(4):1139-1144.
112. Struck MM. 1996. Vaccine R&D success rates and development times. Nature Biotechnology 14(5):591-593.
113. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, Nussenzweig RS, Menard R. 1997. TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell 90(3):511-522.
114. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner DG, Krzych U. 2003. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. Journal of Immunology 171(12):6961-6967.
115. Targett GA. 2005. Malaria vaccines 1985-2005: A full circle? Trends in Parasitology 21(11):499-503.
116. Thomas AW, Carr DA, Carter JM, Lyon JA. 1990. Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. Molecular and Biochemical Parasitology 43(2):211-220.
117. Top FH Jr., Dingerdissen JJ, Habig WH, Quinnan GV Jr., Wells RL. 2000. DoD Acquisition of Vaccine Production. Report to the Secretary of Defense by the Independent Panel of Experts, Dec 2000. In DoD, 2001. Report on Biological Warfare Defense Vaccine Research and Development Programs. Washington D.C.: Department of Defense. [Online]. Available: http://www.acq.osd.mil/cp/bwdvrdp-july01.pdf [Accessed May 3 2006].
118. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E, Ling IT, Fegeding K, Morgan WD, Ockenhouse C, Birdsall B, Feeney J, Lyon JA, Holder AA. 2001. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. Journal of Molecular Biology 307(5):1381-1394.
119. Vaughn, D. 2006 (January 23). Military Infectious Diseases Reseach Program. Paper pre- sented at the Institute of Medicine Workshop on Military Malaria Vaccine Development, Silver Spring, Maryland. Institute of Medicine Committee onDoD Malaria Vaccine Research-A Program Review.
120. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, de Taisne C, Norman JA, Hoffman SL. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282(5388):476-480.
121. Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T, Banania JG, Chattopadhyay R, de la Vega P, Richie TL, Tornieporth N, Doolan DL, Kester KE, Heppner DG, Norman J, Carucci DJ, Cohen JD, Hoffman SL. 2004. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. Journal of Immunology 172:561-569.
122. Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, Charoenvit Y, Epstein JE, Luke T, Freilich DA, Norman J, Hoffman SL. 2005. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infection and Immunity 73(5):2863-2872.
123. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV. 2005. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences USA 102(13):4836-4841.
124. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. 1988. CD8+ T cells (cytotoxic/ suppressors) are required for protection in mice immunized with malaria sporozoites. Proceedings of the National Academy of Sciences USA 85(2):573-576.
125. WHO (World Health Organization). 1986. Chemotherapy of Malaria. Geneva, Switzerland: World Health Organization.
126. WHO. 2002. The World Health Report 2002:Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization.
127. WHO. 2005. Initiative for Vaccine Research. [Online]. Available: http://www.who.int/ vaccine_research/documents/en/malaria_table.pdf [Accessed 3 May 2006].
128. Zavala F, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, Nussenzweig RS, Nussenzweig V. 1985. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228(4706):1436-1440.